High tibial osteotomy as a first step in knee preservationHigh tibial osteotomy repositions the tibia to shift weight-bearing from damaged inner knee cartilage to the healthier outer compartment. For younger, active patients, the procedure preserves the natural joint and potentially extends its working life by a decade or more.High tibial osteotomy repositions the tibia to shift weight-bearing from damaged inner knee cartilage to the healthier outer compartment. For younger, active patients, the procedure preserves the natural joint and potentially extends its working life by a decade or more.
ChondroFiller Injection Evidence Patients Should WeighInjected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.Injected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.
ACI versus MACI for Knee Cartilage RepairMACI seeds cultured cartilage cells onto a porcine-collagen scaffold fixed with fibrin glue; ACI injects them as liquid suspension sealed with a sutured flap. This mechanical difference determines recovery time, complication risk, and surgical complexity.MACI seeds cultured cartilage cells onto a porcine-collagen scaffold fixed with fibrin glue; ACI injects them as liquid suspension sealed with a sutured flap. This mechanical difference determines recovery time, complication risk, and surgical complexity.
ChondroFiller vs Liquid Cartilage for focal cartilage defectsAn injectable collagen scaffold sets into a gel at body temperature and recruits the body's own progenitor cells to repair cartilage over 12–24 months. ChondroFiller is the device name; Liquid Cartilage denotes the same scaffold combined with the patient's own mesenchymal cells in a single appointment.An injectable collagen scaffold sets into a gel at body temperature and recruits the body's own progenitor cells to repair cartilage over 12–24 months. ChondroFiller is the device name; Liquid Cartilage denotes the same scaffold combined with the patient's own mesenchymal cells in a single appointment.
Knee cartilage repair versus stem cell therapyEstablished cartilage repair using autologous chondrocytes shows 10–17 year durability for focal knee defects; mesenchymal stem cell therapies have not been tested in large-scale trials against them.Established cartilage repair using autologous chondrocytes shows 10–17 year durability for focal knee defects; mesenchymal stem cell therapies have not been tested in large-scale trials against them.
ChondroFiller injection versus knee replacement for focal defectsChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
Knee cartilage damage left untreated and when repair helpsCartilage lacks blood vessels, nerve fibres, and lymph channels, so repair cells cannot reach injuries and pain does not warn of damage, allowing lesions to expand silently until they become clinically serious.Cartilage lacks blood vessels, nerve fibres, and lymph channels, so repair cells cannot reach injuries and pain does not warn of damage, allowing lesions to expand silently until they become clinically serious.
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
Who qualifies for ChondroFiller injectionChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.ChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.
OATS Mosaicplasty Knee Recovery TimelineFull recovery from OATS mosaicplasty spans 6–12 months, extending to 12–18 months for competitive sport, because transplanted bone-and-cartilage plugs require time for biological integration and graft maturation.Full recovery from OATS mosaicplasty spans 6–12 months, extending to 12–18 months for competitive sport, because transplanted bone-and-cartilage plugs require time for biological integration and graft maturation.
ChondroFiller injection cost in the UKChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.ChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.
Ten-Year Success Rates for OATS MosaicplastyTen-year success rates for OATS mosaicplasty span 72–89% in young, active patients; failure rates drop to 12.5–14% in optimal candidates (under 40, lesion under 3 cm²) but rise to 38–40% in older patients with larger defects.Ten-year success rates for OATS mosaicplasty span 72–89% in young, active patients; failure rates drop to 12.5–14% in optimal candidates (under 40, lesion under 3 cm²) but rise to 38–40% in older patients with larger defects.